D. Boral Capital Reiterates "Buy" Rating for Cytosorbents (NASDAQ:CTSO)

D. Boral Capital reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $10.00 target price on the medical research company's stock.

Separately, StockNews.com assumed coverage on shares of Cytosorbents in a research report on Wednesday, March 26th. They set a "hold" rating on the stock. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $4.67.

Cytosorbents Price Performance

Cytosorbents stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.97. 151,955 shares of the company were exchanged, compared to its average volume of 144,157. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The business's 50 day simple moving average is $1.07 and its two-hundred day simple moving average is $1.04. The company has a market capitalization of $53.04 million, a P/E ratio of -2.69 and a beta of 0.78.

Remove Ads

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $9.20 million during the quarter, compared to analysts' expectations of $10.09 million. Analysts forecast that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. Skylands Capital LLC raised its position in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after buying an additional 26,195 shares during the period. Millennium Management LLC acquired a new position in Cytosorbents in the fourth quarter valued at $30,000. Northern Trust Corp grew its position in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after acquiring an additional 16,701 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Cytosorbents during the fourth quarter worth about $99,000. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.